title: Therapy of occult hepatitis B virus infection and prevention of reactivation.
abstract: Occult hepatitis B virus infection (OBI) is highly prevalent worldwide. In some cases, it is a consequence of infection with variant viruses mutated in the S gene and producing a surface antigen not recognized by diagnostic kits. In most cases, OBI is due to a strong inhibition of hepatitis B virus (HBV) activities exerted by host defense mechanisms. OBI may reactivate in patients undergoing immunosuppressive therapy and/or chemotherapy with the possibility of a consequent development of acute hepatitis that may lead to hepatic failure. Hematological malignancies and therapeutic schedules including rituximab are the conditions most frequently associated with OBI reactivation. However, this event may occur in a large number of additional clinical and therapeutic settings. Identification of patients prone to undergo reactivation is of great importance for promptly starting a proper antiviral therapy that may stop the HBV reactivation and prevent its clinical sequelae.
authors.affiliation: Division of Clinical and Molecular Hepatology, University Hospital of Messina, Messina, Italy.
authors.forename: Giovanni
authors.initials: G
authors.lastname: Raimondo
authors.forename: Roberto
authors.initials: R
authors.lastname: Filomia
authors.forename: Sergio
authors.initials: S
authors.lastname: Maimone
mesh_terms: D058846:Antibodies, Monoclonal, Murine-Derived / Q000009:adverse effects / Q000627:therapeutic use; D058070:Asymptomatic Diseases / Q000453:epidemiology*; D004279:DNA, Viral / Q000235:genetics; D006509:Hepatitis B / Q000175:diagnosis* / Q000188:drug therapy / Q000517:prevention & control*; D006514:Hepatitis B Surface Antigens / Q000235:genetics; D006515:Hepatitis B virus / Q000235:genetics; D006801:Humans; D007165:Immunosuppression Therapy; D012008:Recurrence; D000069283:Rituximab; D014775:Virus Activation / Q000235:genetics*
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D004279:DNA, Viral; D006514:Hepatitis B Surface Antigens; D000069283:Rituximab